Doubek M - Search Results

1

Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: can we compare real life data to the results from clinical trials?

Zackova D, Klamova H, Dusek L, Muzik J, Polakova KM, Moravcova J, Jurcek T, Dvorakova D, Racil Z, Pospisil Z, Oltova A, Michalova K, Brezinova J, Razga F, Doubek M, Cetkovsky P, Trneny M, Mayer J. Zackova D, et al. Among authors: doubek m. Am J Hematol. 2011 Mar;86(3):318-21. doi: 10.1002/ajh.21942. Epub 2011 Feb 15. Am J Hematol. 2011. PMID: 21328429 Free article. No abstract available.

2

[Must we be really concerned about amphotericin B toxicity in oncology patients?].

Mayer J, Doubek M. Mayer J, et al. Among authors: doubek m. Cas Lek Cesk. 1998 Oct 19;137(20):632-6. Cas Lek Cesk. 1998. PMID: 9863267 Czech.

3

Must we really fear toxicity of conventional amphotericin B in oncological patients?

Mayer J, Doubek M, Vorlìcek J. Mayer J, et al. Among authors: doubek m. Support Care Cancer. 1999 Jan;7(1):51-5. doi: 10.1007/s005200050224. Support Care Cancer. 1999. PMID: 9926976

4

[Activation of autologous hematopoietic stem cell transplants with interleukin-2].

Hájek R, Korístek Z, Vinklárková J, Janovská E, Klabusay M, Doubek M, Dvoráková D, Bourková L, Dusek L, Adler J, Mayer J, Vorlícek J. Hájek R, et al. Among authors: doubek m. Cas Lek Cesk. 2001 Jul 19;140(14):430-5. Cas Lek Cesk. 2001. PMID: 11503192 Czech.

5

[Prevention of mycotic infections in oncology patients with regard to the toxicity of antimycotic agents].

Doubek M, Mayer J, Horký D, Doubek J, Rácil Z, Vorlícek J. Doubek M, et al. Among authors: doubek j. Vnitr Lek. 2002 Mar;48(3):248-54. Vnitr Lek. 2002. PMID: 11968587 Review. Czech.

6

[Safety of long-term administration of conventional amphotericin B in oncology patients].

Doubek M, Mayer J, Horký D. Doubek M, et al. Cas Lek Cesk. 2002 Mar;141(5):156-9. Cas Lek Cesk. 2002. PMID: 11998223 Czech.

7

Interleukin-2 activation of haematopoietic stem cells.

Hájek R, Korístek Z, Vinklárková J, Janovská E, Klabusay M, Doubek M, Dvoráková D, Bourková L, Dusek L, Büchler T, Adler J, Adam Z, Penka M, Mayer J, Vorlícek J. Hájek R, et al. Among authors: doubek m. Acta Med Austriaca. 2002;29(2):61-7. doi: 10.1046/j.1563-2571.2002.02005.x. Acta Med Austriaca. 2002. PMID: 12050948

8

Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures: animal experiments and clinical study.

Mayer J, Doubek M, Doubek J, Horký D, Scheer P, Stepánek M. Mayer J, et al. Among authors: doubek j, doubek m. J Infect Dis. 2002 Aug 1;186(3):379-88. doi: 10.1086/341662. Epub 2002 Jul 11. J Infect Dis. 2002. PMID: 12134234

9

Increased expression of fibroblast growth factor receptor 3 in CD34+ BCR-ABL+ cells from patients with chronic myeloid leukemia.

Dvorak P, Dvorakova D, Doubek M, Faitova J, Pacholikova J, Hampl A, Mayer J. Dvorak P, et al. Among authors: doubek m. Leukemia. 2003 Dec;17(12):2418-25. doi: 10.1038/sj.leu.2403152. Leukemia. 2003. PMID: 14562121

10

Reduced-intensity allografting for chronic myeloid leukemia in the first chronic phase.

Doubek M, Vitek A, Mayer J. Doubek M, et al. Haematologica. 2004 Apr;89(4):ELT03. Haematologica. 2004. PMID: 15075116 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

245 results

Search Page

Filters